Search

everythinglearnresearchcommunity

for

Search:↓

Lower SHBG levels may increase the risk of PCOS.

Congenital Adrenal Hyperplasia is a genetic disorder with two forms, causing symptoms like early puberty and severe acne, but can be identified through screening and treated with glucocorticoids.

Finasteride treats enlarged prostate, improves urinary flow, but may cause sexual side effects.

HNG may help prevent the negative effects of chemotherapy on sperm production and white blood cell counts.

Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.

Hormone imbalances from the pituitary, thyroid, and adrenal glands can cause infertility, but treating these disorders can improve fertility.

Men with benign prostatic hyperplasia are more likely to have metabolic syndrome than those without it.

Cyproterone acetate is the preferred treatment for women's hyperandrogenism when estrogen/progestogen use is safe.

Glucocorticoids are powerful anti-inflammatory drugs that must be used carefully to avoid serious side effects.

Stress, hypothyroidism, drug intake, and anemia are important factors in women's diffuse hair loss.

Longer CAG repeat lengths in the androgen receptor gene are linked to higher testosterone levels in women with PCOS.

All women with Polycystic Ovary Syndrome (PCOS) in a study had at least one skin disorder, with the most common being excessive hair growth, acne, dark skin patches, hair loss, and oily skin.

Severe vertex pattern hair loss may indicate a higher risk for artery plaque buildup.

Finasteride shows promise for female hair loss, but more research needed.

The document concludes that early recognition and treatment of PCOS in adolescents is crucial for managing symptoms and long-term health risks.

Oxidative stress is a key factor in the development of Polycystic Ovary Syndrome, and weight management can improve symptoms.

Use "female pattern hair loss" term, assess androgen excess, treat with minoxidil and other medications if needed.

The conclusion is that PCOS is caused by ovarian sensitivity to hormones and disrupted hormone control, possibly due to ovarian factors, and more research is needed.

Testosterone replacement may help some postmenopausal women with symptoms like fatigue and low libido, but more research is needed to fully understand its effects.

A boy with GAPO syndrome had hair loss similar to male pattern baldness without hormone issues, possibly due to skin or blood vessel problems.

Sex hormones like estrogen and testosterone may affect COVID-19 severity differently in men and women, potentially influencing prevention and treatment strategies.

Certain genetic variations in the SHBG gene are linked to an increased or decreased risk of PCOS in Mediterranean women.

Greek women with PCOS have a higher risk of metabolic syndrome and are more likely to be overweight compared to healthy controls.

Genetic defects in the glucocorticoid receptor gene can cause conditions with abnormal sensitivity to stress hormones, and other factors may also affect this sensitivity.

New hair loss treatments may include topical medications, injections, and improved transplant methods.

Low SHBG and high FAI, FT, and DHEAS levels are effective in identifying PCOS.

Testosterone may influence COVID-19 severity and outcomes.

Orlistat helped reduce weight and testosterone in obese women with PCOS but did not significantly affect other androgens or cholesterol levels.

Early balding in young Indian men may indicate a higher risk of metabolic syndrome and potential heart disease.

Advancements in male reproductive medicine are ongoing, but more research and improved treatments are needed in several areas.